2017

  • Salubris won the title of “the Most Competitive Enterprise in Guangdong Province”.

  • Salubris won the title of “Guangdong - Hong Kong Superior Partner of Cleaner Production (Manufacturing)”.

  • Salubris was recognized to be one of the “2016 Top 100 Enterprises in China’s Pharmaceutical Industry”.

  • Salubris was entitled as a “Public Welfare Enterprise Contributing to Medical Capacity Promotion in Chinese Counties”.

  • Pingshan Pharmaceutical Factory won the award of “Cleaner Production Enterprise in Guangdong Province” from Guangdong Provincial Cleaner Production Association.

  • Salubris was conferred with “China Red Cross Charity Medal” by the Red Cross Society of China.

  • Salubris (Huizhou) was recognized as a national high-tech enterprise.

  • Taijia (Clopidogrel Bisulfate Tablets) and Taijianing (Bivalirudin) won the honor of “the Most Competitive Brand in Guangdong Province”.


2016

  • Salubris was entitled to be a National Demonstration Enterprise in Technology Innovation.

  • Salubris was evaluated to be an AAA level high-integrity enterprise in pharmaceutical industry in Guangdong Province.

  • “the Most Competitive Enterprise in Guangdong Province” and “the Most Competitive Brand in Guangdong Province”.

  • Salubris won the award of “Best New Technology Pioneer on the List of Public Praise of Chinese Listed Companies in 2016”.

  • Salubris ranked in the 20 Most Competitive Pharmaceutical Listed Companies in China in 2016.

  • Ye Yuxiang, President of the Company, won the honorary title of “Top 10 Innovative Character of Chinese Listed Company Brands in 2016”.

  • Salubris was listed in “Top 100 Chinese Listed Companies in Innovative Brand Value in 2016”.

  • Salubris was listed in “Top 10 Pharmaceutical Listed Companies in R&D Investment in 2016”.

  • Salubris won the award of “the Best Industrial Enterprise of China’s Pharmaceutical R&D Product Line in 2016”.

  • Taijia won the award of “the Generic Drug with the Highest Clinical Alternative Value of the Most Influential Brand in China’s Pharmaceutical Innovation”.

  • Salubris was recognized as one of the 2015 Top 100 Enterprises in China’s Pharmaceutical Industry.


2015

  • Salubris ranked in “2015 Forbes Asia’s Top 200 Medium and Small-sized Listed Enterprises”.

  • Ye Yuxiang, President of the Company, won “2015 Forbes China’s Best CEO of Listed Companies”.

  • Ye Chenghai, Chairman of the Company, was awarded to be “Top 10 Innovative Character for Chinese Economy in 2014”.

  • Ye Chenghai, Chairman of the Company, was entitled to be an “Outstanding Chinese Innovative Entrepreneur”.

  • Salubris won the title of “Member Enterprise with the Greatest Social Responsibility”.

  • Salubris won the title of “Guangdong Provincial Integrity Demonstration Enterprise” for eight consecutive years (2007-2014).

  • Salubris won the title of “Guangdong Provincial Sincerest Enterprise for 2014”.

  • Salubris won the titles of “Top 100 Golden Bull Listed Companies”, “Golden Bull Most Efficient Companies” and “Golden Bull Best Small and Medium-sized Growth Companies” for 2014.

  • Salubris was listed in the “10 Most Valuable Companies Listed on SMEs Board in China” for two consecutive years.

  • Salubris was listed in the “20 Most Competitive Pharmaceutical Listed Companies in China” for three consecutive years.

2014

  • Salubris was selected as “Guangdong Provincial Outstanding Proprietary Brand”.

  • Salubris was awarded to be a “Model Enterprise in Health Management”.

  • Salubris was listed in the “Top 100 Enterprises in Pharmaceutical Industry in Shenzhen”.

  • Salubris was rated as the first “Top 100 Quality Enterprises in Shenzhen”

  • Salubris was evaluated to an “Advanced Unit of Market Expansion in Pharmaceutical Industry in Guangdong Province”.

2013

  • Allisartan Isoproxil Tablet (Xinlitan) was selected as “2013 Top 10 Significant Prescription Medicine”.

  • Salubris won the title of “Guangdong Provincial Integrity Demonstration Enterprise” for six consecutive years. 

  • Salubris was selected as “Guangdong Provincial Demonstration Enterprise for Proprietary Innovation”.

  • Salubris won the award of “Best Industrial Board of Chinese Listed Companies”.

  • Salubris was selected as an “Outstanding Product Brand of Anti-infection in China’s Chemical Pharmaceutical Industry”.

  • Salubris was listed in “Top 100 Industrial Enterprises with Comprehensive Strength in China’s Chemical Pharmaceutical Industry”.

  • Salubris was selected as an “Outstanding Innovative Enterprise Brand in China’s Chemical Pharmaceutical Industry”.

  • Salubris was listed in “Top 100 Enterprises in China’s Pharmaceutical Industry”.

  • Salubris was listed in the “20 Most Competitive Pharmaceutical Listed Companies in China”.

  • Salubris was listed in “Forbes Asia’s Top 200 Medium and Small-sized Listed Enterprises”.

2012

  • Salubris R&D Center changed to Salubris Technology Center and was recognized as a “National Level Corporate Technology Center”.

  • Three of its projects were selected as “National Key New Drug Development Projects of the 12th Five-Year Plan”. 

  • Salubris was recognized as one of the “National 5th Innovative Pilot Enterprises”.

  • Salubris was recognized as a “Key High-tech Enterprise of China’s Torch Program”.

2011

  • Salubris ranked in “Forbes China’s 20 Most Potential Enterprises”.

  • Salubris won “Technology Progress Award in Shenzhen”.

  • Xinxiting (Cefoxitin Sodium for Injection) was selected as “Guangdong Provincial Famous Trademark”.

  • Three Salubris products were awarded as “Guangdong Provincial New Technological Products”.

  • Salubris was selected as “Guangdong Provincial Backbone Enterprise in Strategic Emerging Industry”.

  • Salubris was listed in the “Top 100 Enterprises in China’s Pharmaceutical Industry”.

  • Salubris was listed in the “20 Most Competitive Pharmaceutical Listed Companies in China”.

2010

  • Salubris ranked in the “Top 10 Listed Companies with Core Competitiveness in Chemical Agents”.

  • Salubris was awarded to be a “Superior Enterprise of Intellectual Property in Shenzhen”. 

  • Salubris and Xinliwei were selected as “Guangdong Provincial Famous Trademarks”.

  • Salubris ranked in the “Top 100 Golden Bull Listed Companies” again.

  • Salubris won the award of “Top 500 Asian Brands”.

  • Five Salubri products were awarded as “Guangdong Provincial Proprietary Innovation Products”.

  • The Company won “Technology Progress Award in Shenzhen”.

  • Salubris was listed in “Top 50 Enterprises with Comprehensive Strength in Pharmaceutical Industry in Guangdong Province”.

2009

  • Salubris was recognized as a “National High-tech Enterprise”.

  • Salubris won the awards of “New Record Enterprise in Shenzhen” and “Triumph of Corporate Integrity”. 

  • Salubris ranked in the “Top 100 Golden Bull Listed Companies”.

  • Salubris ranked in the “Top 20 Enterprises in Industrial Chemical Bulk Drugs/ Chemical Medicine and Preparation Manufacturing in Guangdong Province”.

2008

  • Salubris won the title of “Proprietary Innovative Leading Brand of Chinese Enterprises”.

  • Salubris was evaluated to be a “Pharmaceutical Enterprise with AAA Credit Rating in Guangdong Province”. 

  • Salubris R&D Center was recognized as a “Municipal Level R&D Center in Shenzhen (under the category of technology centers)”.

  • Salubris was listed in the first “Industrial Leading Enterprises of Proprietary Innovation”.

  • Salubris was selected as “Guangdong Provincial Innovative Enterprise in Pharmaceutical Industry over Thirty Years of the Reform and Opening-up Policy”.

  • Salubris won “Guangdong Provincial Outstanding Contribution Award in Pharmaceutical Industry over Thirty Years of the Reform and Opening-up Policy”.

  • Two Salubris projects won the title of “Guangdong Provincial Outstanding Projects for Technological Innovation in Pharmaceutical Industry over Thirty Years of the Reform and Opening-up Policy”.

  • Taijia won the title of “Guangdong Provincial Most Influential Brand in Pharmaceutical Industry over Thirty Years of the Reform and Opening-up Policy”.


2007

  • Salubris won Guangdong Provincial Science and Technology Award.

  • Salubris was awarded to be a “Famous Brand in Shenzhen”. 

2006

  • Salubris ranked in “Top 50 Enterprises in Pharmaceutical Industry in Guangdong Province”.

  • Salubris won the first title of first “Top 100 Super Commercial Brands in Shenzhen”. 


2005

  • Four of its products including Taijia were selected to be Guangdong Provincial high-tech products. 

2002

  • “Taijia” (Clopidogrel Bisulfate Tablets) and “Xinminting” (Desloratadine Tablets) were selected as national key new products in 2002.

  • Salubris was selected to be “Shenzhen Municipal Technologically Advanced Enterprise”.

  • Salubris was evaluated to be “Shenzhen Municipal High-tech Enterprise”.